Key facts today
Moderna's stock rose 9.5% to $32.75 on Tuesday, its biggest single-day gain since March 5, amid ongoing challenges in the pharmaceutical sector and shifting demand for its Covid-19 vaccine.
−425 ARS
−3.26 T ARS
2.96 T ARS
About Moderna, Inc.
Sector
Industry
CEO
Stéphane Bancel
Website
Headquarters
Cambridge
Founded
2010
ISIN
AR0666228538
FIGI
BBG01MDJMFS6
Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.
Related stocks
MRNA looking strong at cmpModerna remains in a precarious transition phase—from COVID-revenue dependency toward a diversified vaccine portfolio. Technically, momentum favors upside in the short-term, but fundamentals and macro-regulatory factors suggest caution. If its RSV and flu/COVID combo rollouts succeed and regulatory
MRNA: The Wager No One Wants to Talk AboutModerna (MRNA) has become a pariah in many portfolios. Between reputational overhangs, political weaponization of its COVID success, and fresh regulatory pressures like the labeling requirement just triggered by Florida, the company has seemingly absorbed wave after wave of bad press.
But that’s th
$MRNA – Long-Term Setup Brewing | Major Move Incoming?Moderna ( NASDAQ:MRNA ) may be gearing up for a multi-month reversal after a prolonged downtrend. Price action is compressing in a tight base, suggesting a potential 6+ month breakout could be in the cards.
📊 Key Technical Notes:
Trading near long-term support with signs of accumulation
Bullish d
Bullish wedge coiling up; bird flu incoming ?
1. Over the past year moderna is down 85% and from its pandemic highs, down 90%+ so simply that alone tells you the stock is quite cheap and beaten down. It is currently trading at 2020 levels as if a world changing pandemic never happened.
2. Moderna is currently trading around its book value o
MODERNA $305 | Bidding at $220 and $150 Informed Players and speculators at Sub $100 levels are booking gains
we wait for additional drwadowns and re accomodation ACCUMULATION of designated Bankers for the next run up OR cycle
Vaccine COViD was intense HiV was the sell on News..
we await next Drama and Biden Policy on Healthcare etc..
A Long-term Bullish Trend ?With an upcoming Earnings report we can observe rather uncertain future behavior.
But since the trend has been bearish for a longer period of time and the price is "nearly" at the same position which was achieved for the first time in early April in 2019, we can, mostly based only on the technical
Moderna (MRNA) Shares Plunge Nearly 9%Moderna (MRNA) Shares Plunge Nearly 9%
Moderna (MRNA) shares tumbled by approximately 8.9%, falling below $29—marking their lowest level since April 2020, when global markets were shaken by the COVID-19 pandemic.
Since the start of 2025, MRNA’s share price has declined by around 32%.
Why Did MR
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where MRNA is featured.